Did U read this...$$$ here:
"The main catalyst TooNiceStocks found for BioSante will likely be in the form of the Valentine’s Day PDUFA date for Bio-T-Gel, a testosterone gel for male hypogonadism, a condition in which men don’t produce enough testosterone and as a result suffer fatigue, decreased energy, reduced sexual desire and depressed mood. The drug was initially developed by BioSante, but has since been licensed to Teva Pharmaceutical Industries, Inc., a large global pharmaceutical company with a multi-billion dollar market capitalization. Teva is responsible for all Bio-T-Gel regulatory and marketing activities. As a result of the agreement, BioSante received $1.5 million upfront and will receive royalties upon commercialization. The time leading up to the PDUFA date is running out and Microcap, along with Smallcap investors will likely begin planning their next move, if any, on whether this potential gel will be approved.
TooNiceStocks also notes that BioSante owns exclusive development and commercial rights to its pipeline of cancer fighting drugs through its BioSante Immunotherapy drugs. The FDA’s approval of Dendreon’s Provenge for prostate cancer in 2010 pushed the technology into the spotlight, and BioSante has positioned itself with its own immunotherapy pipeline at differing levels of development. Detailed information may be found on the company’s website but a brief overview of this pipeline shows positive results for three of their vaccines in Chronic Myeloid Leukemia (CML), Acute Myeloid Leukemia (AML) and Pancreatic Cancer.
BioSante did have a huge setback with the LibiGel late-stage trials with likely a lot of time and money that could possibly lead to an end to that program. However looking at the overall picture of the company, TooNiceStocks also found that their last quarterly statement noted the company still had about $70 million in cash and equivalents."
COMPANY TRADES FOR ITS CASH ON HAND. POTENTIAL FDA APPROVAL ON FEB 14 IS NOT IN ANY WAY FACTORED HERE. YOU CALL TO MAKE IF YOU LIKE $$$ THE WAY I DO
AI
